Boehringer Ingelheim grows faster than the pharmaceutical market
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim continued to grow in 2009, increasing its net sales by 9.7% to EUR 12.7 billion (2008: EUR 11.6 billion). This was announced by the company at its Annual Press Conference. Even without taking into account positive currency effects, growth was once again above the average growth for the worldwide pharmaceutical market, at 6.7%.
Despite Concern, Americans Aren't Protecting Themselves Against Diabetes
- Details
- Category: Abbott
Diabetes affects more than 23 million people in the United States today and another 54 million people have pre-diabetes, according to the Centers for Disease Control and Prevention (CDC).
Roche Group sustained its strong sales growth in the first three months of 2010
- Details
- Category: Roche
Group sales grew 9% in local currencies (6% in Swiss francs; 15% in US dollars) to 12.2 billion Swiss francs. The Pharmaceuticals Division's sales increased 10% in local currencies (6% in Swiss francs; 15% in US dollars) to 9.7 billion Swiss francs, maintaining its above-market growth.
Novo Nordisk's operating profit increased by 15% in the first quarter of 2010
- Details
- Category: Novo Nordisk
Reported operating profit increased by 15% to DKK 4,382 million. Adjusted for the impact from currencies, operating profit in local currencies increased by around 20%.
Novartis healthcare portfolio generates strong growth in first quarter of 2010
- Details
- Category: Novartis
Novartis delivered a strong performance in the first quarter of 2010 - particularly the rapid expansion of recently launched products and important regulatory approvals achieved for new medicines and vaccines - as the Group made progress with a sharp focus on innovation, growth and productivity.
World Bank and Pfizer Announce Initiative to Help Improve Healthcare Delivery
- Details
- Category: Pfizer
The World Bank and Pfizer Inc. announced they will collaborate to improve the healthcare infrastructure, specifically the supply chain, in developing countries, starting with Africa.
Superior efficacy of Victoza® (liraglutide) compared to Januvia® (sitagliptin)
- Details
- Category: Novo Nordisk
The Lancet published online the results of the first study comparing the once-daily human GLP-1 analogue, Victoza® (liraglutide) with a DPP-4 inhibitor, Januvia®. The 26-week trial showed that Victoza® produced significantly greater reductions in HbA1c, fasting plasma glucose (FPG) and body weight than Januvia®, with similar or better overall treatment satisfaction.[1]
More Pharma News ...
- Pfizer Discontinues Phase 3 Trial of Sutent® in Advanced Hepatocellular Carcinoma
- Amgen's First Quarter 2010 Revenue Increased 9 Percent to $3.6 Billion
- Abbott Reports Strong First Quarter Results
- Sandoz to acquire Oriel Therapeutics, gaining rights to portfolio of respiratory products
- Bayer HealthCare Marks 2010 World Hemophilia Day with EUR 250,000 Contribution
- Novo Nordisk launches international survey into the psychosocial effects of living with haemophilia
- Long-term efficacy and tolerability of Vimpat® (lacosamide)